Heska Q3 revenue, loss up
LOVELAND — Heska Corp (Nasdaq: HSKA) reported consolidated revenue of $60.2 million and a net loss of $1.6 million in its third quarter ending Sept. 30. Its consolidated revenue rose 6.4% as its net loss widened by 69.5%, compared with the same period last year.
Heska makes and sells veterinary diagnostic and specialty products.
A press release on its quarterly results highlighted North American growth in lab products and point-of-care imaging, higher gross margins, and acquisitions to increase products and services to veterinarians.
In the third quarter, Heska bought Italy-based veterinary lab BiEsseA SRL for $7.7 million on July 1 and Maryland-based…
Related Posts
-
Enliven Therapeutics finished the third quarter with $292 million in cash, which, the company said,…
-
Biodesix Inc. (Nasdaq: BDSX), a life-sciences company that specializes in developing tools to detect lung…
-
Edgewise Therapeutics Inc., a Boulder-based muscle disease biopharmaceutical company, increased its research and development spending…
-
Arca Biopharma has completed its merger with Oruka Therapeutics Inc.
